Thymosin β4 sustained release from poly(lactide-co-glycolide) microspheres: synthesis and implications for treatment of myocardial ischemia.
A sustained release formulation for the therapeutic peptide thymosin β4 (Tβ4) that can be localized to the heart and reduce the concentration and frequency of dose is being explored as a means to improve its delivery in humans. This review contains concepts involved in the delivery of peptides to the heart and the synthesis of polymer microspheres for the sustained release of peptides, including Tβ4. Initial results of poly(lactic-co-glycolic acid) microspheres synthesized with specific tolerances for intramyocardial injection that demonstrate the encapsulation and release of Tβ4 from double-emulsion microspheres are also presented.
Department of Cardiothoracic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. Jeffrey.Thatcher@UTSouthwestern.edu
Jeffrey E
JE
Thatcher
Tré
T
Welch
Robert C
RC
Eberhart
Zoltan A
ZA
Schelly
J Michael
JM
DiMaio
D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D008863:Microspheres; D017202:Myocardial Ischemia / Q000188:drug therapy*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013947:Thymosin / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use*; D000099201:Thymosin beta(4)
D019344:Lactic Acid; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013947:Thymosin; D000099201:Thymosin beta(4)